{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:28:28Z","timestamp":1791509308834,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Funded Zhejiang Provincial Medical and Health Science and Technology Program","award":["2021KY1033"],"award-info":[{"award-number":["2021KY1033"]}]},{"name":"the Ningbo Medical and Health Brand Discipline","award":["PPXK2024-01"],"award-info":[{"award-number":["PPXK2024-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04288-0","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:30:33Z","timestamp":1751625033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efgartigimod therapy for immune checkpoint inhibitor\u2013associated myasthenia gravis with myositis: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Feiteng","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"6","key":"4288_CR1","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","volume":"18","author":"M Collins","year":"2020","unstructured":"Collins M, et al. Management of patients with immune checkpoint Inhibitor-Induced enterocolitis: A systematic review. Clin Gastroenterol Hepatol. 2020;18(6):1393\u2013e14031.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"4288_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","volume":"24","author":"AZ Munir","year":"2024","unstructured":"Munir AZ, et al. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Nat Rev Cancer. 2024;24(8):540\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4288_CR3","doi-asserted-by":"publisher","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","volume":"10","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely JR Jr., et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology. 2021;10(1):1875639.","journal-title":"Oncoimmunology"},{"issue":"10","key":"4288_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, et al. Neurological complications associated with Anti-Programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216\u201322.","journal-title":"JAMA Neurol"},{"key":"4288_CR5","doi-asserted-by":"publisher","unstructured":"Guidon AC, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021;9(7). https:\/\/doi.org\/10.1136\/jitc-2021-002890.","DOI":"10.1136\/jitc-2021-002890"},{"issue":"8","key":"4288_CR6","first-page":"685","volume":"23","author":"S Yao","year":"2020","unstructured":"Yao S, et al. [Immune checkpoint Inhibitors-induced myasthenia gravis: from diagnosis to treatment]. Zhongguo Fei Ai Za Zhi. 2020;23(8):685\u20138.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"6","key":"4288_CR7","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","volume":"270","author":"S Rossi","year":"2023","unstructured":"Rossi S, et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J Neurol. 2023;270(6):2975\u201386.","journal-title":"J Neurol"},{"issue":"1","key":"4288_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319.","journal-title":"J Immunother Cancer"},{"key":"4288_CR9","unstructured":"Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG), in StatPearls. 2024, StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Appaji Rayi declares no relevant financial relationships with ineligible companies."},{"key":"4288_CR10","doi-asserted-by":"publisher","unstructured":"Gao W, et al. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia Gravis. J Immunother Cancer. 2022;10(11). https:\/\/doi.org\/10.1136\/jitc-2022-005970.","DOI":"10.1136\/jitc-2022-005970"},{"issue":"7","key":"4288_CR11","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055\u20138.","journal-title":"Cancer Sci"},{"issue":"27","key":"4288_CR12","doi-asserted-by":"publisher","first-page":"e7350","DOI":"10.1097\/MD.0000000000007350","volume":"96","author":"YH Chen","year":"2017","unstructured":"Chen YH, et al. Nivolumab-induced myasthenia Gravis in a patient with squamous cell lung carcinoma: case report. Med (Baltim). 2017;96(27):e7350.","journal-title":"Med (Baltim)"},{"key":"4288_CR13","doi-asserted-by":"publisher","first-page":"1372861","DOI":"10.3389\/fneur.2024.1372861","volume":"15","author":"Y Qin","year":"2024","unstructured":"Qin Y, et al. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024;15:1372861.","journal-title":"Front Neurol"},{"issue":"6","key":"4288_CR14","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.esmoop.2021.100317","volume":"6","author":"B Jordan","year":"2021","unstructured":"Jordan B, et al. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open. 2021;6(6):100317.","journal-title":"ESMO Open"},{"key":"4288_CR15","doi-asserted-by":"publisher","unstructured":"Kaira K, Mouri A, Imai H, Yamaguchi O, Kagamu H. Clinical issue of myasthenia gravis related to immune checkpoint inhibitors. Curr Oncol Rep. 2024;26(9):1113\u20139. https:\/\/doi.org\/10.1007\/s11912-024-01571-0.","DOI":"10.1007\/s11912-024-01571-0"},{"issue":"9","key":"4288_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00520-023-07987-x","volume":"31","author":"JM Weaver","year":"2023","unstructured":"Weaver JM, et al. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series. Support Care Cancer. 2023;31(9):518.","journal-title":"Support Care Cancer"},{"key":"4288_CR17","doi-asserted-by":"publisher","unstructured":"Nelke C, Pawlitzki M, Kerkhoff R, Schroeter CB, Aktas O, Neuen-Jacob E, et al. Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade. Neurol Neuroimmunol Neuroinflamm. 2023;11(1):e200177. https:\/\/doi.org\/10.1212\/NXI.0000000000200177.","DOI":"10.1212\/NXI.0000000000200177"},{"key":"4288_CR18","doi-asserted-by":"publisher","unstructured":"Zhou Y, Jiang S. Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker. Pathogens. 2023;12(6):817. https:\/\/doi.org\/10.3390\/pathogens12060817.","DOI":"10.3390\/pathogens12060817"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04288-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04288-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04288-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:30:34Z","timestamp":1751625034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04288-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4288"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04288-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by Ethics Committee of Ningbo Medical Center Lihuili Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The written consent of the patient has been obtained for her personal clinical details to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}